Pancreatic Cancer Research

ResearcherHarbin Medical UniversityNo recent work listed

Shuliang Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-6761-4855; OpenAlex author ID A5071976989. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper

Papers 3

  1. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1002/1878-0261.13279↗
  2. The Biological Function Delineated Across Pan-Cancer Levels Through lncRNA-Based Prognostic Risk Assessment Factors for Pancreatic Cancer. Last author DOI 10.3389/fcell.2021.694652↗
  3. Dauricine suppresses the growth of pancreatic cancer in vivo by modulating the Hedgehog signaling pathway. Co-author DOI 10.3892/ol.2019.10790↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yunyan Gu · 1 shared paper, 2022 · strength 0.14
  2. Kaidong Liu · 1 shared paper, 2022 · strength 0.14
  3. Min Zou · 1 shared paper, 2022 · strength 0.14
  4. Xu-Dong Tang · 1 shared paper, 2021 · strength 0.14
  5. Yan Zhang · 1 shared paper, 2021 · strength 0.14
  6. Lili Zhong · 1 shared paper, 2019 · strength 0.11
  7. Yingbo Zhang · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.